This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
PROCEPT BioRobotics' (PRCT) HYDROS System Gets FDA Clearance
by Zacks Equity Research
PROCEPT BioRobotics (PRCT) announces the FDA 510(k) clearance of its HYDROS Robotic System for providing better BPH treatment.
Cardinal Health (CAH) to Open New Distribution Center in Ohio
by Zacks Equity Research
Cardinal Health's (CAH) new center is set to integrate cutting-edge technology and automation, enhancing efficiency, storage capacity and quality of service.
CollPlant (CLGN), Stratasys Initiate Study for Breast Implants
by Zacks Equity Research
CollPlant (CLGN) and Stratasys announce the initiation of a pre-clinical study to focus on the ability of implants to grow natural breast tissue and completely degrade over time.
Avinger (AVGR) Launches Pantheris LV to Boost PAD Treatment
by Zacks Equity Research
Avinger (AVGR) fully launches Pantheris LV, the first image-guided atherectomy system for large vessels, thus enhancing peripheral artery disease treatment with advanced technology.
Reasons to Hold Cencora (COR) Stock in Your Portfolio for Now
by Zacks Equity Research
Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Here's Why You Should Retain Nevro (NVRO) Stock for Now
by Zacks Equity Research
Strength in Nevro's (NVRO) Senza Platform raises optimism about the stock.
Brookdale (BKD) Down 7% Since Q2 Earnings Miss on Lower Interest
by Zacks Equity Research
Brookdale (BKD) expects adjusted EBITDA for the third quarter in the range of $90-$95 million.
Why You Should Add HCA Healthcare (HCA) to Your Portfolio Now
by Zacks Equity Research
HCA Healthcare (HCA) remains well-poised for growth on growing emergency room visits, buyouts and solid cash flows.
Boston Scientific (BSX), Silk Road Merger Delayed for Review
by Zacks Equity Research
Boston Scientific (BSX) withdraws its premerger notification and report form to give the U.S. FTC more time to review the proposed acquisition of Silk Road Medical.
Enovis (ENOV) Introduces STAR Ankle With e+ Polyethylene
by Zacks Equity Research
Enovis (ENOV) brings the first mobile-bearing ankle system with e+ Polyethylene, which offers enhanced durability, stability and longevity for improved patient outcomes.
Zacks.com featured highlights Universal Health, General Motors, EnerSys and Itron
by Zacks Equity Research
Universal Health, General Motors, EnerSys and Itron have been highlighted in this Screen of The Week article.
Zacks Industry Outlook Highlights HCA Healthcare, Universal Health Services, Tenet Healthcare, Acadia Healthcare and Community Health Systems
by Zacks Equity Research
HCA Healthcare, Universal Health Services, Tenet Healthcare, Acadia Healthcare and Community Health Systems have been highlighted in this Industry Outlook article.
5 Hospital Stocks Poised to Benefit From Strong Industry Growth
by Kaibalya Pravo Dey
The Zacks Medical-Hospital industry will gain from increasing admissions and cybersecurity and technological advancements. Companies like HCA, UHS, THC, ACHC and CYH are poised to gain from these trends.
Microbot Medical (MBOT) Gets Quality Certification for its System
by Zacks Equity Research
Microbot Medical (MBOT) secures ISO 13485:2016 certification for its LIBERTY Endovascular Robotic System, a milestone that streamlines European and FDA regulatory compliance for future commercialization.
McKesson (MCK) Stock Gains 18% YTD: What's Driving the Rally?
by Harshit Gupta
McKesson's (MCK) shares rally on the back of solid fundamentals. Increasing volumes of prescription and specialty drugs boost the top line.
Should Value Investors Buy Universal Health Services (UHS) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
4 Stocks Trading Near 52-Week High With More Upside Potential
by Vasundhara Sawalka
Investors target stocks that have lately been on a bull run. Stocks like PPC, THC, DVA and UHS are seeing price strength and have a high chance of carrying the momentum forward.
4 Low P/CF Stocks to Buy Now as Market Confidence Soars
by Sumit Singh
Value investing is essentially about selecting stocks that are usually cheap but fundamentally sound. UHS, GM, ENS & ITRI boast low P/CF ratios.
Masimo (MASI) Gets New Suitors for Its Consumer Business Sale
by Zacks Equity Research
Masimo (MASI) receives unsolicited requests from multiple entities for acquiring its consumer business. The company already received a non-binding term sheet confirmation from a third party in May.
Reasons to Add Intuitive Surgical (ISRG) to Your Portfolio Now
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to raise optimism among investors owing to its strength in robotics.
Integer Holdings (ITGR) Gains 21.9% YTD: What's Driving the Stock?
by Zacks Equity Research
Integer Holdings (ITGR) shares gain on the back of growth in the Medical segment. However, fluctuations in raw material prices and the oil and energy market are concerning.
DexCom's (DXCM) G7 CGM Coverage Expanded for Quebec Residents
by Zacks Equity Research
DexCom (DXCM) announces that Quebec residents aged two years and older living with type 1 diabetes may now be eligible to receive coverage for Dexcom G7.
The Joint (JYNT) Forays Into San Francisco Chiropractic Market
by Zacks Equity Research
This year, The Joint (JYNT) intends to open 60-70 new franchised clinics compared with 104 opened last year.
Humacyte's (HUMA) ATEV BLA Review Period Extended by FDA
by Zacks Equity Research
Humacyte's (HUMA) Biologic License Application for its ATEV faces a delay as the FDA extends its review timeline, recognizing the product's potential impact on vascular trauma treatment.
Why Universal Health Services (UHS) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.